Sugi Predict

Sugi Predict / Compounds / SCHEMBL2432075

SCHEMBL2432075

SCHEMBL2432075

CCOC(=O)CCc1ccc(O)c(CC)c1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.59
▸ CYP4A11 Q02928 3/20 0.59
▸ BACE1 P56817 1/20 0.57
▸ APP P05067 2/20 0.56
▸ CYP4Z1 Q86W10 1/20 0.48
▸ IAPP P10997 3/20 0.47
▸ PDE3B Q13370 1/20 0.46
▸ PDE3A Q14432 1/20 0.46
▸ P2RY12 Q9H244 1/20 0.46
▸ ALOX5 P09917 1/20 0.43
▸ OR51E2 Q9H255 1/20 0.43
▸ HSD17B1 P14061 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ YWHAG P61981 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25118388 0.90 CYP4F2 (0.55) CYP4F2CYP4A11BACE1APPCYP4Z1
SCHEMBL14818348 0.88 CYP4F2 (0.54) CYP4F2CYP4A11BACE1APPCYP4Z1
SCHEMBL14213070 0.88 APP (0.58) CYP4F2CYP4A11BACE1APPCYP4Z1
SCHEMBL490911 0.87 APP (0.73) CYP4F2CYP4A11APPCYP4Z1IAPP
SCHEMBL30291871 0.87 APP (0.73) CYP4F2CYP4A11APPCYP4Z1IAPP
SCHEMBL8418573 0.86 FDFT1 (0.52) CYP4F2CYP4A11BACE1APPCYP4Z1
SCHEMBL8984895 0.86 CYP4F2 (0.61) CYP4F2CYP4A11APPCYP4Z1IAPP
SCHEMBL16048663 0.86 BACE1 (0.58) CYP4F2CYP4A11BACE1APPIAPP
SCHEMBL1549436 0.86 CYP4F2 (0.61) CYP4F2CYP4A11APPCYP4Z1IAPP
SCHEMBL9121505 0.85 CYP4Z1 (0.53) CYP4F2CYP4A11BACE1APPCYP4Z1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3409671-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 — — EP disclosed
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICALS NV (BE) 2020-04-14 — — US disclosed
CN-106414434-B Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes 詹森药业有限公司 2019-12-31 — — CN disclosed
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2019-03-07 — — US disclosed
EP-3409671-A1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Janssen Pharmaceutica NV (BE) 2018-12-05 — — EP disclosed
US-10118922-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2018-11-06 — — US disclosed
EP-3114123-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-04-25 — — EP disclosed
EP-3114123-A1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Janssen Pharmaceutica NV (BE) 2017-01-11 — — EP disclosed
EP-2970161-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Janssen Pharmaceutica, N.V. (BE) 2016-01-20 — — EP disclosed
CN-105209446-A GPR120 agonists for the treatment of type ii diabetes JANSSEN PHARMACEUTICA NV 2015-12-30 — — CN disclosed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 — — WO disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 — — US disclosed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 — — WO disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 — — US disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 — — US disclosed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 — — EP disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 — — US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GLP1R, GCGR CYP4F2 2590/4885CYP4A11 631/4885BACE1 3343/4885
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR CYP4F2 1483/4885CYP4A11 1325/4885BACE1 3533/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR CYP4F2 1483/4885CYP4A11 1325/4885BACE1 3533/4885
US-10118922-B2 GPR120 agonists for the treatment of type II diabetes GPR119, GLP1R, GCGR CYP4F2 2590/4885CYP4A11 631/4885BACE1 3343/4885
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes GPR119, GLP1R, GCGR CYP4F2 2590/4885CYP4A11 631/4885BACE1 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.